Litigation Details for Aquestive Therapeutics, Inc. v. Biodelivery Sciences International, Inc. (E.D.N.C. 2018)
✉ Email this page to a colleague
Aquestive Therapeutics, Inc. v. Biodelivery Sciences International, Inc. (E.D.N.C. 2018)
Docket | ⤷ Try a Trial | Date Filed | 2018-10-30 |
Court | District Court, E.D. North Carolina | Date Terminated | 2019-08-07 |
Cause | 28:1338 Patent Infringement | Assigned To | James C. Dever III |
Jury Demand | Plaintiff | Referred To | |
Patents | 8,765,167 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Aquestive Therapeutics, Inc. v. Biodelivery Sciences International, Inc.
Details for Aquestive Therapeutics, Inc. v. Biodelivery Sciences International, Inc. (E.D.N.C. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2017-01-12 | 1 | of United States Patent No. 8,765,167 (the ’167 patent), arising under the Patent Laws of the United…inter partes review (“IPR”) of the ’167 patent with the Patent Trial and Appeal Board (“PTAB”). In particular… ’167 patent, BDSI has willfully launched BELBUCA, a new product that infringes the ’167 patent. In this…over 150 patents and several FDA approvals. 15. On July 1, 2014, the ’167 patent, entitled…Laura Moss. That patent was assigned to MonoSol. A true and correct copy of the ’167 patent is attached | External link to document | |
2019-08-06 | 99 | Order on Motion to Dismiss | and Laura Moss obtained United States Patent No. 8,765, 167 (the "'167 paterii''…States Patent and Trademark Office's ("PTO") inter partes review of the patent at issue… 2 of 7 Patent Trial and Appeal Board ("PTAB"). See id. Despite the pending patent infringement…offers to sell, or sells any patented invention ... infringes the patent." 35 U.S.C. § 271(a). When…also have known of the patent and that the induced acts constitute direct patent infringement. See Commil | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |